

## H. Lundbeck A/S

Ottiliavej 9  
DK-2500 Valby, Copenhagen  
CVR number: 56759913

Tel +45 36 30 13 11  
Fax +45 36 43 82 62

E-mail [investor@lundbeck.com](mailto:investor@lundbeck.com)  
[www.lundbeck.com](http://www.lundbeck.com)



## Corporate Release

### **H. Lundbeck A/S increases its share capital by 40,104 shares (0.0203 % of outstanding shares) as a result of employee warrant exercise**

**Valby, Denmark, 23 February 2016** - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 200,520, as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 13,435 shares at DKK 115, 3,897 shares at DKK 102, 2,326 shares at DKK 97, 8,662 shares at DKK 121 and 11,784 shares at DKK 113. Proceeds to the company are DKK 4,547,835 (approximately USD 672,001). The increase corresponds to approximately 0.0203 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the time of registration of the capital increase. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority. Lundbeck's current share capital amounts to DKK 986,506,405 and will after the capital increase be DKK 986,706,925. The capital increase is expected to be finalized shortly.

### **Lundbeck contacts**

#### Investors:

Palle Holm Olesen  
Vice President, Investor Relations  
[PALO@lundbeck.com](mailto:PALO@lundbeck.com)  
+45 36 43 24 26

#### Media:

Mads Kronborg  
Director, Corporate Communication  
[MAVK@lundbeck.com](mailto:MAVK@lundbeck.com)  
+45 36 43 30 00

### **About Lundbeck**

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.

Read more at [www.lundbeck.com/global/about-us/progress-in-mind](http://www.lundbeck.com/global/about-us/progress-in-mind).



Our approximately 5,300 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site [www.lundbeck.com](http://www.lundbeck.com) and connect with us on Twitter at [@Lundbeck](https://twitter.com/Lundbeck).

### **Safe Harbor/Forward-Looking Statements**

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.